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Background
To assess coverage of harm reduction services for HIV-
infected patients in Estonia and their integration with
HIV care; to identify barriers to integrated services
provision.
Methods
We reviewed HIV surveillance documents, administra-
tive data and scientific literature, and interviewed key
informants providing treatment and harm reduction ser-
vices in North-Eastern county of Estonia.
Results
E s t o n i ah a dt h eh i g h e s ti n c i d e n c eo fH I Vi n f e c t i o ni n
Europe with 472 cases per million and an adult HIV
prevalence of 1,3% in 2007, the second-highest in Eur-
ope. Majority of new cases occur in the North-Eastern
county, with incidence exceeding 4 times that of Estonia
as a whole (183 vs 47 per 100 000). The Estonian epi-
demic is driven by injection drug use, and local studies
have revealed a 40-90% prevalence of HIV among injec-
tion drug users (IDUs). HIV treatment is provided by
state-funded public health-care system. At end of 2008
1006 patients were receiving HAART. Harm reduction
services are provided by non-profit organizations
(usually state funded). There are 7 centers for metha-
done substitution therapy (649 patients treated at end of
2008); 36 syringe exchange programs; 2 centers for free
and anonymous STI services. Yet in different regions
only 6-28% of IDUs report currently receiving treatment
for drug use and 5-12% receiving HAART. The main
challenge and strategic goal of the National HIV/AIDS
Prevention Strategy remains coverage of IDUs by treat-
ment and harm reduction services. The major barrier
identified was failure to provide well integrated services
to those in need. The underlying factors leading to the
barrier were substantial misperceptions in regards to the
utility of methadone substitution therapy among HIV
medical care providers.
Discussion
In the current resource constrained environment
improvement and integration of already existing services
would ensure sustainability of the national HIV preven-
tion strategy. Barriers to integration need to be deli-
neated and addressed.
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